

Title: Real-world experience of methotrexate in the treatment of skin diseases: an Italian Delphi consensus

Running head: Methotrexate in Dermatology

Authors:

Giovanni Damiani^{1,2,3,4}, Paolo

Amerio⁵, Federico Bardazzi⁶, Carlo G. Carrera⁷, Andrea Conti⁸, Francesco Cusano⁹, Paolo Dapavo¹⁰, Clara DeSimone^{11,12}, Maya ElHachem¹³, Gabriella Fabbrocini¹⁴, Paolo Gisondi¹⁵, Francesco Loconsole¹⁶, Giuseppe Micali¹⁷, Iria Neri¹⁸, Aurora Parodi¹⁹, Stefano Piaserico²⁰, Marco Romanelli²¹, Luca Stingeni²², METHOD study working group, Paolo D.M. Pigatto^{1,2}.

Affiliations:

1. Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
2. Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
3. PhD Degree Program in Pharmacological Sciences, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
4. Italian Center of Precision Medicine and Chronic Inflammation, University of Milan, Milan, Italy.
5. Dermatologic Clinic, Department of Medicine and Aging Science, University "G. d'Annunzio", Chieti-Pescara, Italy.
6. Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
7. Fondazione Cà Granda IRCCS Maggiore Policlinico Hospital, Milan, Italy.
8. Dermatology Unit, Ospedale Infermi di Rimini, AUSL Romagna, Rimini, Italy
9. Dermatology Unit, G. Rummo Hospital, Benevento, Italy.
10. Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
11. Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
12. UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
13. Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
14. Section of Dermatology- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
15. Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy.
16. Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy.
17. Dermatology Clinic, University of Catania, Catania, Italy.
18. Dermatology, IRCCS Sant'Orsola-Malpighi Polyclinic University Hospital, University of Bologna, Bologna, Italy.

19. DiSSal Dermatology Clinic University of Genoa, Polyclinic Hospital
San Martino IRCCS Genoa, Italy
20. Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy.
21. University of Pisa, Pisa, Italy.
22. Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

METHOD study working group: Giuseppe Alessandrini¹ ; Gabriella Andreassi² ; Veronica Arese³ ; Nicoletta Bernardini⁴ ; Maria Rita Bongiorno⁵ ; Riccardo Borroni⁶ ; Alexandra MG Brunasso Verneti⁷ ; Pier Luigi Bruni⁸ ; Giacomo Caldarola⁹ ; Elena Campione¹⁰ ; Antonio Carpentieri¹¹ ; Martino Carriero¹² ; Franco Castelli¹³ ; Marina Castriota¹⁴ ; Angelo Cattaneo¹⁵ ; Emilia Cerulli¹⁶ ; Karin Chersi¹⁷ ; Michela Cicoletti⁸ ; Paola Colasanti¹⁸ ; Monica Corazza¹⁹ ; Mario Cordedda²⁰ ; Emanuele Claudio Cozzani²¹ ; Aldo Cuccia²² ; Domenico D'Amico²³ ; Stefano Dastoli²⁴ ; Anna Rita Dell'Anna²⁵ ; Antonella Di Cesare²⁶ ; Vito Giuseppe Di Lernia²⁷ ; Valentina Dini²⁸ ; Maria Esposito²⁹ ; Carmen Silvia Fiorella³⁰ ; Santo Raffaele Mercuri³¹ ; Maria Francesca Gaiani³² ; Giovanna Galdo³³ ; Lucia Gallo³⁴ ; Marco Galluzzo^{35,36} ; Matteo Claudio Garavaglia³⁷ ; Alessandro Gatti³⁸ ; Claudia Giofrè³⁹ ; Claudio Guarneri⁴⁰ ; Jacqueline Kussini⁴¹ ; Serena Lembo⁴² ; Luigi Ligrone⁴³ ; Cinzia Masini⁴⁴ ; Giampiero Mazzocchetti⁴⁵ ; Matteo Megna³⁴ ; Gennaro Melchionda⁴⁶ ; Antonio Miracapillo⁴⁷ ; Pietro Morrone⁴⁸ ; Cristina Mugheddu⁴⁹ ; Maria Letizia Musumeci⁵⁰ ; Patrizia Nespoli⁵¹ ; Giulia Odorici⁵² ; Gloria Orlando⁵³ ; Giovanni Domenico Palazzo⁵⁴ ; Fabrizio Panarese⁵⁵ ; Salvatore Panduri⁵⁶ ; Massimiliano Pazzaglia⁵⁷ ; Alexia Pedron⁵⁸ ; Michele Pezza⁵⁹ ; Angelo Piccirillo⁶⁰ ; Federigo Pioli⁶¹ ; Federico Pirro⁹ ; Miriam Pizzolato⁶² ; Roberto Porciello⁶³ ; Francesca Prestinari⁶⁴ ; Nella Maria Grazia Pulvirenti⁶⁵ ; Andrea Romani⁶⁶ ; Francesca Romano⁶⁷ ; Luigi Rossiello⁶⁸ ; Sandra Schianchi⁶⁹ ; Genoveffa Scotto di Luzio⁷⁰ ; Zelda Seia⁷¹ ; Stefania Sorbara⁷² ; Davide Luigi Strippoli⁶⁴ ; Elena Stroppiana⁷³ ; Franca Taviti⁷⁴ ; Pompilio Trevisi⁷⁵ ; Emanuele Trovato⁷⁶ ; Maria Teresa Uzzauto⁷⁷ ; Anna Verrone⁷⁸ ; Silvia Vichi⁷⁹ ; Leonardo Zichichi⁸⁰.

METHOD study working group affiliations: ¹Dermatology and Venereology Private Practice, Gallipoli, Lecce, Italy; ²Dermatologic Clinic, Department of Medicine and Aging Science, University G D'Annunzio Chieti-Pescara, Chieti, Italy; ³Unit of Dermatology, Department of Medical Sciences, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy; ⁴Department of Medico-surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy; ⁵Section of Dermatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy; ⁶Unit of Dermatology, IRCCS Humanitas Clinic, Rozzano, Milan, Italy; ⁷Department of Dermatology, Galliera Hospital, Genoa, Italy; ⁸UOC Clinical Dermatology, Azienda Ospedaliera S. Maria, Terni, Italy; ⁹Department of Dermatology, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; ¹⁰Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; ¹¹Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy; ¹²Dermatology Unit, Poliambulatorio Grottaglie, Grottaglie, Italy; ¹³Dermatology Unit, Koelliker Hospital, Turin, Italy; ¹⁴Dermatology Private Practice, Caprarica di Lecce, Italy; ¹⁵IRCCS Fondazione Ca' Granda, Ospedale maggiore Policlinico, Milan, Italy; ¹⁶Hospital Pharmacy Unit, Santa Maria della Misericordia Hospital, Hospital of Perugia, Perugia, Italy; ¹⁷Dermatological Clinic, ASUGI - Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy; ¹⁸Dermatology Unit, "Ospedale del Mare", Naples, Italy; ¹⁹Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; ²⁰UOC Dermatology, San Gennaro Hospital, Naples, Italy; ²¹Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; ²²Dermatology, San Donato Hospital, Arezzo, Surgical Department, Usl Toscana Sudest, Italy; ²³Clinical Dermatology, Azienda Ospedaliera "Pugliese

Ciaccio", Catanzaro, Italy; ²⁴Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy; ²⁵Clinical Dermatology, ASL Bari, Bari, Italy; ²⁶Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy; ²⁷Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; ²⁸Department of Dermatology, University of Pisa, Pisa, Italy; ²⁹Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; ³⁰Clinical Dermatology, Ospedale Dimiccoli di Barletta, Barletta, Italy; ³¹Unit of Dermatology, IRCCS San Raffaele Hospital, Milan, Italy; ³²Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy; ³³Dermatology Unit, Moscati Hospital, Avellino, Italy; ³⁴Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; ³⁵Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; ³⁶Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy; ³⁷Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy; ³⁸ULSS 2 Marca Trevigiana Ospedale Ca' Foncello Treviso, Treviso, Italy; ³⁹U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; ⁴⁰Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy; ⁴¹Dermatology and Laserklinik, Biberach, Germany; ⁴²Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy; ⁴³Dermatology Unit, San Giovanni di Dio e Ruggi D'Aragona University Hospital, Scuola Medica Salernitana, Salerno, Italy; ⁴⁴UOC Dermatology, Ospedale dei Castelli, Rome, Italy; ⁴⁵UOSD Dermatologia ASL1 Pescara, Pescara, Italy; ⁴⁶Dermatology Unit, Casa Sollievo della Sofferenza-IRCCS, San Giovanni Rotondo, Italy; ⁴⁷Dermatology Unit, Ospedale Generale Regionale "F. Miulli", Acquaviva delle Fonti, Italy; ⁴⁸UOC Dermatology, Azienda Ospedaliera di Cosenza, Cosenza, Italy; ⁴⁹Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; ⁵⁰Dermatology Clinic, University of Catania, Catania, Italy; ⁵¹UOS Dermatology, ASL Teramo, Teramo, Italy; ⁵²Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; ⁵³Unit of Dermatology, Department of Medicine, University of Padua, Padua, Italy; ⁵⁴Clinical Dermatology, Azienda Sanitaria Locale di Matera, Matera, Italy; ⁵⁵Department of Dermatology, University "G D'Annunzio" University of Chieti-Pescara, Chieti, Italy; ⁵⁶UO Dermatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; ⁵⁷Dermatology Division IRCCS Sant'Orsola Policlinico University of Bologna, Bologna, Italy; ⁵⁸Dermatology Unit, Ospedale Carlo Poma, Mantova, Italy; ⁵⁹Dermatology Department, ASL Benevento, Benevento, Italy; ⁶⁰AO Ospedale San Carlo di Potenza, Italy; ⁶¹Clinical Dermatology, ASL Toscana NordOvest, Cecina, Italy; ⁶²Dermatology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; ⁶³Dermatology Unit, Ospedale "Sandro Pertini", Rome, Italy; ⁶⁴Dermatology Unit, Ospedale Manzoni, Lecco, Italy; ⁶⁵Private Practice, Giarre, Italy; ⁶⁶Dermatology Unit, Istituto Dermoclinico Vita Cutis, Milan, Italy; ⁶⁷Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy; ⁶⁸Department of Dermatology, A.O.R.N. "A. Cardarelli", Naples, Italy; ⁶⁹Centro Grandi Ustionati, Cesena, Italy; ⁷⁰AO Caserta San Sebastiano e Sant Anna UOS Di Dermatologia, Caserta, Italy; ⁷¹Clinical Dermatology, asl CN1, Cuneo, Italy; ⁷²Clinical Dermatology, Azienda Socio Sanitaria Ligure n. 4, Chiavari, Italy; ⁷³Department of Medical Science, Dermatology Clinic, "Città della Salute e della Scienza of Turin," Turin, Italy; ⁷⁴UOSD Dermatology, USL Toscana Centro-Prato Hospital, Prato, Italy; ⁷⁵Private Practice, Campi Salentina, Italy; ⁷⁶Department of Medical, Surgical and Neurological Science, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy; ⁷⁷U.O.C. Dermatologia, ASL Salerno, Ospedale "A:Tortora"-Pagani, Salerno, Italy; ⁷⁸Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy; ⁷⁹AUSL Romagna Infermi Hospital, Rimini, Italy; ⁸⁰Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy.

Corresponding author:
Giovanni Damiani, MD

UOC Dermatology, Istituto Ortopedico Galeazzi,
Via Riccardo Galeazzi, 4, 20161 Milan, Italy
Tel: +39 02 662141. Fax: +39 02 66214016 Mail: dr.giovanni.damiani@gmail.com
ORCID ID: 0000-0002-2390-6505

Supplementary Table 1. Licensed and unlicensed indications for methotrexate in adults. ¹.

	Strength of recommendation	Dose suggested ¹
<i>Licensed indications</i> Psoriasis	A	7.5-25 mg/week [1]
<i>Unlicensed indications</i> Lupus erythematosus – systemic and cutaneous (DLE, SCLE, chilblain lupus, lupus profundus)*	B	10-20 mg/week [2]
Cutaneous sarcoidosis*	C	10-20 mg/week [3]
Lymphoproliferative disorders (including CTCL, mycoses fungoides, lymphomatoid papulosis, pityriasis lichenoides)	C	10 to 60 mg/week [4]
Alopecia areata	D	10-25 mg/ week [5]
Atopic eczema	D	10-25 mg/week [6,7]
Bullous pemphigoid*	D	2-15 mg/week [8]
Chronic spontaneous/idiopathic urticaria	D	10-25 mg/week [9]
Cutaneous small vessel vasculitis (including cutaneous polyarteritis nodosa, Behcet disease and erythema elevatum diutinum)	D	10-15 mg/week [10]
Dermatomyositis	D	7.5-25 mg/ week [11]
Granuloma annulare (included generalised type)	D	7.5-17.5 mg/week [12]
Hailey-Hailey disease	D	7.5-15mg/week [13]
Langerhans cell histiocytosis	D	15-20 mg/week [14]
Necrobiosis lipoidica	D	15 mg/week [15]
Lichen planus (included oral type)	D	7.5-15 mg/weel [16]
Pemphigus*	D	10-20 mg/week [17-18]

Pyoderma gangrenosum	D	10-15 mg /week [19,20]
Systemic sclerosis (including limited systemic sclerosis)/localized scleroderma (morphea)*	D	15–25 mg once weekly [21]

* MTX generally used as a steroid-sparing agent rather than monotherapy.

¹ The dose range include both initiation and maintenance.

References:

- [1] van Huizen AM, Menting SP, Gyulai R, et al. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. *JAMA Dermatol.* 2022;158(5):561-572.
- [2] Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. *J Rheumatol.* 1999;26(6):1275-9.
- [3] Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. *J Am Acad Dermatol.* 1991;24(3):451-4.
- [4] Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. *J Am Acad Dermatol.* 1996;34(3):470-81.
- [5] Chartaux E, Joly P. Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis. *Ann Dermatol Venereol.* 2010;137:507–513.
- [6] Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. *J Eur Acad Dermatol Venereol.* 2010 Jan;24(1):43-9.
- [7] Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F; “Skin Allergy” Group of SIDeMaST; “ADOI” (Associazione Dermatologi Ospedalieri Italiani); “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale); Pigatto PDM. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). *Dermatol Ther.* 2019;32(6):e13121.
- [8] Wojtczak M, Nolbrzak A, Woźniacka A, Żebrowska A. Can Methotrexate Be Employed as Monotherapy for Bullous Pemphigoid? Analysis of Efficiency and Tolerance of Methotrexate Treatment in Patients with Bullous Pemphigoid. *J Clin Med.* 2023 Feb 18;12(4):1638.
- [9] Sandhu J, Kumar A, Gupta SK. The therapeutic role of methotrexate in chronic urticaria: A systematic review. *Indian J Dermatol Venereol Leprol.* 2022;88(3):313-321.
- [10] Stack PS. Methotrexate for urticarial vasculitis. *Ann Allergy* 1994; 72:36-38.
- [11] Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, Hohlfeld R, Melms A, Melzer N, Rösler K, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H. Guidelines on dermatomyositis--excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. *J Dtsch Dermatol Ges.* 2016 Mar;14(3):321-38.
- [12] Joshi TP, Duvic M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. *Am J Clin Dermatol.* 2022 Jan;23(1):37-50.

- [13] Arjona-Aguilera C, Jiménez-Gallo D, Villegas-Romero I, Valenzuela-Ubiña S, Linares-Barrios M. Subcutaneous methotrexate for Hailey-Hailey disease: two case reports and review of the literature. *J Dtsch Dermatol Ges.* 2021 Feb;19(2):278-281.
- [14] Patel S, Alhaji M, Brimhall C. A Novel Case of Multicentric Reticulohistiocytosis Associated with Renal Cell Carcinoma Successfully Treated with Infliximab and Methotrexate. *Case Rep Dermatol.* 2023 Jan 9;15(1):10-16.
- [15] West EA, Warren RB, King CM. A case of recalcitrant necrobiosis lipoidica responding to combined immunosuppression therapy. *J Eur Acad Dermatol Venereol.* 2007 Jul;21(6):830-1.
- [16] Lajevardi V, Ghodsi SZ, Hallaji Z, Shafiei Z, Aghazadeh N, Akbari Z. Treatment of erosive oral lichen planus with methotrexate. *J Dtsch Dermatol Ges.* 2016 Mar;14(3):286-93.
- [17] Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 1 - current therapies. *Expert Rev Clin Immunol.* 2019 Oct;15(10):1047-1060.
- [18] Bardazzi F, Loi C, Chessa Marco A, Di Altobrando A, Filippi F, Lacava R, Viviani F, Balestri R, Leuzzi M, Sacchelli L. Therapeutic approaches and targets for treatment of autoimmune bullous diseases. *Dermatol Ther.* 2021 Sep;34(5):e15032.
- [19] Breznik V, Marko PB. A Case of Overlapping Clinical Features of Idiopathic Granulomatous Mastitis, Hidradenitis Suppurativa, and Pyoderma Gangrenosum Successfully Treated with Adalimumab. *Case Rep Dermatol.* 2022 May 3;14(2):98-106
- [20] Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. *Cutis.* 1996 May;57(5):326-8.
- [21] Papara C, De Luca DA, Bieber K, Vorobyev A, Ludwig RJ. Morphea: The 2023 update. *Front Med (Lausanne).* 2023 Feb 13;10:1108623.

Supplementary Table 2. Characteristic of participants. The characteristics of the 69 and 54 participants participating in Delphi rounds 2 and 3, respectively, are unknown since voting was anonymous, but refer to the 85 who initially agreed to participate.

Characteristic	N (%) N=85
Age (mean $\pm$ SD)	50.5 $\pm$ 10.0
Age group (years)	
<40	16 (18.8)
41-50	29 (34.1)
51-60	19 (22.2)
>60	21 (24.7)
Sex	
Male	39 (45.9)
Female	46 (54.1)
Type of practice	
Hospital	54 (63.5%)
Non Hospital	31 (36.5%)